A role for ceramide glycosylation in resistance to oxaliplatin in colorectal cancer

• Published in: Experimental cell research Vol. 388; no. 2; p. 111860
• Main Authors: Madigan, James P., Robey, Robert W., Poprawski, Joanna E., Huang, Huakang, Clarke, Christopher J., Gottesman, Michael M., Cabot, Myles C., Rosenberg, Daniel W.
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 15.03.2020
• Subjects: Chemoresistance; Colorectal cancer; Glucosylceramide; Glucosylceramide synthase; Oxaliplatin; Glucosylceramide; Oxaliplatin; Glucosylceramide synthase; Colorectal cancer; Chemoresistance
• ISSN: 0014-4827; 1090-2422
• DOI: 10.1016/j.yexcr.2020.111860

There is growing evidence to support a role for the ceramide-metabolizing enzyme, glucosylceramide synthase (GCS), in resistance to a variety of chemotherapeutic agents. Whether GCS contributes to oxaliplatin resistance in colorectal cancer (CRC) has not yet been determined. We have addressed this potentially important clinical issue by examining GCS function in two panels of oxaliplatin-resistant, isogenic CRC cell lines. Compared to parental cell lines, oxaliplatin-resistant cells have increased expression of GCS protein associated with increased levels of the pro-survival ceramide metabolite, glucosylceramide (GlcCer). Inhibition of GCS expression by RNAi-mediated gene knockdown resulted in a reduction in cellular GlcCer levels, with restored sensitivity to oxaliplatin. Furthermore, oxaliplatin-resistant CRC cells displayed lower ceramide levels both basally and after treatment with oxaliplatin, compared to parental cells. GlcCer, formed by GCS-mediated ceramide glycosylation, is the precursor to a complex array of glycosphingolipids. Differences in cellular levels and species of gangliosides, a family of glycosphingolipids, were also seen between parental and oxaliplatin-resistant CRC cells. Increased Akt activation was also observed in oxaliplatin-resistant CRC cell lines, together with increased expression of the anti-apoptotic protein survivin. Finally, this study shows that GCS protein levels are greatly increased in human CRC specimens, compared to matched, normal colonic mucosa, and that high levels of UGCG gene expression are significantly associated with decreased disease-free survival in colorectal cancer patients. These findings uncover an important cellular role for GCS in oxaliplatin chemosensitivity and may provide a novel cellular target for augmenting chemotherapeutic drug effectiveness in CRC.